CDKN2C and Miyoshi myopathy: This is in keeping with alterations in CDKN2C and RB1 being indicators of late stage disease [23, 24], thus the absence of these alterations in FGFR3 mutated cases suggests FGFR3 mutations as early events and RAS-RAF mutations as markers of late stage disease in t(4;14) MM.